(PAHC) Phibro Animal Health - Overview
Stock: Antibacterials, Anticoccidials, Vaccines, Trace Minerals, Specialty Ingredients
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.60% |
| Yield on Cost 5y | 2.41% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 96.9% |
| Payout Ratio | 24.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 49.7% |
| Relative Tail Risk | -18.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.67 |
| Alpha | 116.27 |
| Character TTM | |
|---|---|
| Beta | 1.053 |
| Beta Downside | 0.872 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.46% |
| CAGR/Max DD | 1.29 |
Description: PAHC Phibro Animal Health January 20, 2026
Phibro Animal Health Corp. (NASDAQ: PAHC) is a U.S.–based provider of animal-health and mineral-nutrition products, serving poultry, swine, beef, dairy, aquaculture and companion-animal markets across North America, Latin America, Europe, the Middle East, Africa and Asia-Pacific. The business is organized into three segments – Animal Health, Mineral Nutrition, and Performance Products – and sells through a mix of direct sales offices and feed-manufacturer distributors.
Key recent metrics (FY 2024) show revenue of roughly **$1.04 billion**, a **5.2 % year-over-year increase** driven primarily by higher demand for trace-mineral premixes and antimicrobial-free vaccine solutions. Gross margin improved to **38 %**, reflecting a shift toward higher-value microbial bioproducts and a modest decline in raw-material cost inflation as zinc and copper prices have stabilized. The company’s **EBITDA margin sits near 12 %**, consistent with peers that have successfully transitioned to premium, specialty feed additives.
Sector drivers that materially affect PAHC’s outlook include (1) **global livestock production growth** – the FAO projects a 2.5 % CAGR in meat and dairy output through 2030, expanding feed-additive volumes; (2) **regulatory pressure on antibiotic use** – tighter bans in the EU and U.S. are accelerating adoption of vaccine-based disease control, a niche where PAHC has a strong pipeline; and (3) **commodity price volatility** – fluctuations in copper, zinc and manganese directly impact the cost structure of mineral-nutrition products, making hedging and supply-chain diversification critical. A material shift in any of these factors would warrant revisiting the company’s growth assumptions.
For a deeper quantitative view of PAHC’s valuation metrics, the ValueRay platform offers a concise dashboard worth checking.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 67.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.73 > 1.0 |
| NWC/Revenue: 40.41% < 20% (prev 37.63%; Δ 2.79% < -1%) |
| CFO/TA 0.06 > 3% & CFO 76.8m > Net Income 67.8m |
| Net Debt (712.3m) to EBITDA (184.3m): 3.87 < 3 |
| Current Ratio: 3.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.9m) vs 12m ago 0.73% < -2% |
| Gross Margin: 31.17% > 18% (prev 0.31%; Δ 3085 % > 0.5%) |
| Asset Turnover: 119.0% > 50% (prev 108.3%; Δ 10.70% > 0%) |
| Interest Coverage Ratio: 3.05 > 6 (EBITDA TTM 184.3m / Interest Expense TTM 44.2m) |
Altman Z'' 4.31
| A: 0.41 (Total Current Assets 835.8m - Total Current Liabilities 270.1m) / Total Assets 1.39b |
| B: 0.21 (Retained Earnings 294.4m / Total Assets 1.39b) |
| C: 0.11 (EBIT TTM 134.8m / Avg Total Assets 1.18b) |
| D: 0.16 (Book Value of Equity 174.3m / Total Liabilities 1.07b) |
| Altman-Z'' Score: 4.31 = AA |
Beneish M -2.94
| DSRI: 1.01 (Receivables 217.9m/160.8m, Revenue 1.40b/1.05b) |
| GMI: 1.01 (GM 31.17% / 31.42%) |
| AQI: 0.71 (AQ_t 0.11 / AQ_t-1 0.16) |
| SGI: 1.34 (Revenue 1.40b / 1.05b) |
| TATA: -0.01 (NI 67.8m - CFO 76.8m) / TA 1.39b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of PAHC shares?
Over the past week, the price has changed by +25.34%, over one month by +30.31%, over three months by +21.84% and over the past year by +127.10%.
Is PAHC a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 2
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the PAHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43 | -14% |
| Analysts Target Price | 43 | -14% |
| ValueRay Target Price | 60.3 | 20.5% |
PAHC Fundamental Data Overview February 04, 2026
P/E Forward = 10.5708
P/S = 1.2137
P/B = 5.2214
P/EG = 1.6618
Revenue TTM = 1.40b USD
EBIT TTM = 134.8m USD
EBITDA TTM = 184.3m USD
Long Term Debt = 724.5m USD (from longTermDebt, last quarter)
Short Term Debt = 27.5m USD (from shortTermDebt, last quarter)
Debt = 785.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 712.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.40b USD (1.70b + Debt 785.1m - CCE 85.3m)
Interest Coverage Ratio = 3.05 (Ebit TTM 134.8m / Interest Expense TTM 44.2m)
EV/FCF = 69.95x (Enterprise Value 2.40b / FCF TTM 34.3m)
FCF Yield = 1.43% (FCF TTM 34.3m / Enterprise Value 2.40b)
FCF Margin = 2.45% (FCF TTM 34.3m / Revenue TTM 1.40b)
Net Margin = 4.85% (Net Income TTM 67.8m / Revenue TTM 1.40b)
Gross Margin = 31.17% ((Revenue TTM 1.40b - Cost of Revenue TTM 963.4m) / Revenue TTM)
Gross Margin QoQ = 32.92% (prev 29.05%)
Tobins Q-Ratio = 1.73 (Enterprise Value 2.40b / Total Assets 1.39b)
Interest Expense / Debt = 1.72% (Interest Expense 13.5m / Debt 785.1m)
Taxrate = 26.86% (9.74m / 36.3m)
NOPAT = 98.6m (EBIT 134.8m * (1 - 26.86%))
Current Ratio = 3.09 (Total Current Assets 835.8m / Total Current Liabilities 270.1m)
Debt / Equity = 2.52 (Debt 785.1m / totalStockholderEquity, last quarter 311.7m)
Debt / EBITDA = 3.87 (Net Debt 712.3m / EBITDA 184.3m)
Debt / FCF = 20.77 (Net Debt 712.3m / FCF TTM 34.3m)
Total Stockholder Equity = 277.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.77% (Net Income 67.8m / Total Assets 1.39b)
RoE = 24.43% (Net Income TTM 67.8m / Total Stockholder Equity 277.5m)
RoCE = 13.45% (EBIT 134.8m / Capital Employed (Equity 277.5m + L.T.Debt 724.5m))
RoIC = 9.73% (NOPAT 98.6m / Invested Capital 1.01b)
WACC = 7.10% (E(1.70b)/V(2.48b) * Re(9.80%) + D(785.1m)/V(2.48b) * Rd(1.72%) * (1-Tc(0.27)))
Discount Rate = 9.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.46%
[DCF Debug] Terminal Value 74.53% ; FCFF base≈36.8m ; Y1≈24.2m ; Y5≈11.0m
Fair Price DCF = N/A (negative equity: EV 257.5m - Net Debt 712.3m = -454.9m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 63.60 | EPS CAGR: 19.87% | SUE: 1.97 | # QB: 1
Revenue Correlation: 84.78 | Revenue CAGR: 12.66% | SUE: 1.81 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.69 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-06-30): EPS=2.74 | Chg30d=+0.001 | Revisions Net=+2 | Growth EPS=+31.1% | Growth Revenue=+13.1%
EPS next Year (2027-06-30): EPS=3.02 | Chg30d=-0.001 | Revisions Net=+4 | Growth EPS=+10.1% | Growth Revenue=+3.3%